A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Recruiting

Phase 3

CPX-351 & GilteritinibA Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Sponsor:

Children's Oncology Group

Code:

NCT04293562

Conditions

Acute Myeloid Leukemia

Eligibility Criteria

Sex: All

Age: 0 - 21

Healthy Volunteers: Not accepted

Interventions

Allogeneic Hematopoietic Stem Cell Transplantation

Asparaginase Erwinia chrysanthemi

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-06. This information was provided to ClinicalTrials.gov by Children's Oncology Group on 2025-09-18.